KRAS and colorectal cancer: Remarkably, the generation of a personalised model of a treatment-resistant metastatic KRAS-mutant colorectal cancer in Drosophila larvae has led to the identification of a drug combination, trametinib and zoledronate, that has been used as a treatment for the patient [36], highlighting the potential of Drosophila as a model for personalised medicine.